Enzyme-linked immune antibody detection kit based on synthetic peptide antigen and application of enzyme-linked immune antibody detection kit

Through bioinformatics screening and chemical synthesis of polypeptide antigens, combined with enzyme-linked immunization kits, the problem of insufficient sensitivity and specificity of goat poxvirus antibody detection in the prior art was solved, and efficient and accurate antibody detection effect was achieved.

CN119060143APending Publication Date: 2024-12-03CHINA ANIMAL HUSBANDRY IND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411339114.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing goat poxvirus antibody detection methods have problems with insufficient sensitivity and specificity, and it is difficult to accurately and effectively detect goat poxvirus antibodies in goat serum.

Method used

The bioinformatics method was used to accurately analyze the goat pox virus A27L protein, and the polypeptide segments suitable for ELISA detection were screened out, and a high-purity polypeptide antigen was prepared through chemical synthesis technology to be used for coated antigens of enzyme-linked immunosuppressive kits. Detection was performed in conjunction with enzyme-linked reaction plate.

Benefits of technology

It has achieved high sensitivity and strong specificity detection of goat pox virus antibodies in sheep serum, meeting market demand, and has broad market prospects and good economic and social benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses an enzyme-linked immune antibody detection kit based on a synthetic peptide antigen and application of the enzyme-linked immune antibody detection kit. The kit is a goat pox virus ELISA antibody detection kit and comprises an elisa plate, positive control serum, negative control serum, an elisa secondary antibody, a sample diluent, a 20-time concentrated washing solution, a substrate solution A, a substrate solution B and a stop solution, and the elisa plate is coated with a goat pox virus antigen epitope sequence 3 polypeptide and sequence 4 polypeptide antigen composition. The kit uses the chemically synthesized antigen peptide coated ELISA plate, has the advantages of small antigen dosage, good sensitivity, high specificity and high coincidence rate with commercially available ELISA kits, and can efficiently detect whether the goat pox virus antibody exists or not. The kit disclosed by the invention is high in sensitivity, good in specificity and convenient to operate, and has a good market prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological detection, and more specifically, the present invention relates to an enzyme-linked immunosorbent assay antibody detection kit based on synthetic peptide antigens, which is a goat pox virus ELISA antibody detection kit suitable for goat pox virus antibody detection in goat serum. Background Art

[0002] Sheeppox, also known as variola ovina, includes goat pox (GP) and sheep pox (SP), which are acute, febrile, and contact infectious diseases of sheep and goats caused by goat poxvirus (GTPV) and sheep poxvirus (SPPV) of the genus Capri poxvirus (CaPV) of the Poxviridae family, respectively. It is the most serious of all animal pox diseases, and is endemic. It can infect goats and sheep of different breeds, genders, and ages. The mortality rate of lambs is as high as 100%, and pregnant ewes often have miscarriages. Most sheep lose their productivity after severe sheep pox. The occurrence of this disease brings huge economic losses to the sheep industry, and seriously affects the development of international trade and the sheep industry. Goat pox epidemics have occurred in Inner Mongolia, Gansu, Hebei, Guizhou, Yunnan, and other places in my country, causing great economic losses to the booming goat breeding industry and fur processing industry in my country. The World Organization for Animal Health (OIE) has listed it as an animal disease that must be reported. In the newly revised "List of Category I, II and III Animal Epidemic Diseases" in 2022, it is listed as a Category II animal infectious disease.

[0003] Studies have shown that the genomes of various CaPV isolates are very conservative, and the genome consistency of GTPV and SPPV is greater than 96%. They cross-react in serum and do not cross-infect under natural conditions. Studies have shown that A27L is one of the dominant targets for serotype detection of capripoxvirus and can be used as a diagnostic target for antibody detection of capripoxvirus.

[0004] At present, goat pox live vaccine immunization is mainly used for goat pox disease prevention and control in China. Serological antibody detection is an important means to detect natural infection and evaluate the immune effect of vaccines. Enzyme-linked immunosorbent assay is the mainstream immunoassay technology on the market. It has been widely used in clinical testing. It is fast, convenient and highly sensitive. It does not require special instruments and equipment and can be used for goat pox antibody detection.

[0005] Bioinformatics methods were used to accurately analyze the vaccine strain GTPV AV41 strain A27L sequence, screen out the dominant antigenic epitopes, and prepare synthetic peptide-coated antigens for the detection of GTPV antibodies in goat serum. The goat pox virus ELISA antibody detection kit developed in this study can accurately and effectively detect GTPV antibodies in goat serum, with high sensitivity and good specificity, meeting market requirements. Summary of the invention

[0006] The purpose of the present invention is to provide an indirect ELISA detection kit for detecting goatpox virus antibodies. The kit uses the antigenic epitope polypeptide on the goatpox virus A27L protein as a coating antigen to establish an indirect ELISA method with good specificity, sensitivity and repeatability, which is used to detect whether goatpox virus antibodies are contained in goat serum.

[0007] In order to achieve the above purpose, the present invention firstly uses biological software to analyze the GTPV A27L protein sequence and designs 4 short peptides targeting the A27L protein. The polypeptide sequence is as follows:

[0008] Sequence 1, IFPGDDDETNERNIDHIEKTSGDHGHYEDKLLDL

[0009] Sequence 2, SDEEPNMIKIKNDIKKIINER

[0010] Sequence 3, YSSYISINDDEISNILKDSFISNEEMQI

[0011] Sequence 4, KDFVLRLLVLEKLFQTSVKECNSLKNI

[0012] The inventors found that the enzyme-linked immunosorbent assay kit prepared from the combination of sequence 3 and sequence 4 has very excellent sensitivity and specificity.

[0013] Therefore, the present invention provides a goatpox virus A27L antigen epitope polypeptide composition, which is composed of the polypeptide shown in sequence 3 and the polypeptide shown in sequence 4 in the sequence table.

[0014] The goatpox virus ELISA antibody detection kit of the invention comprises an enzyme-linked reaction plate, a positive control serum, a negative control serum, an enzyme-labeled secondary antibody, a sample diluent, a 20-fold concentrated washing solution, a substrate solution A, a substrate solution B, and a stop solution, wherein the enzyme-linked reaction plate is coated with a goatpox virus A27L antigen epitope polypeptide composition.

[0015] The enzyme-linked reaction plate is a detachable 96-well ELISA plate; the polypeptides in the goatpox virus antigen epitope polypeptide composition are all obtained by chemical artificial synthesis.

[0016] The optimal preparation method and conditions of the enzyme-linked reaction plate are as follows: the goatpox virus antigen epitope polypeptide composition is dissolved in a carbonate solution with a pH of 9.6, and then added to a 96-well polystyrene enzyme-linked reaction plate, with 200 ng of polypeptide or the polypeptide composition in each well, and placed at 2 to 8° C. for 8 to 12 hours to allow the polypeptide antigen to fully bind to the enzyme-linked reaction plate, and then 300 μl / well of a PBS buffer solution containing 10 mg / ml bovine serum albumin (BSA) with a pH of 7.4 is added, and the plate is blocked at 4° C. overnight, and after being dried, the enzyme-linked reaction plate is sealed and stored at 4° C. after drying.

[0017] The positive control serum is a highly immune serum prepared by immunization with a commercial goat pox live vaccine; the positive control serum is obtained by the following steps:

[0018] (1) Animals used in the production were healthy goats aged 6 months, which were isolated and observed for 7 days.

[0019] (2) The immunogen is a commercial goatpox live vaccine. Three immunizations are performed according to the immunization dose provided in the instructions, at 0, 3 and 6 weeks (the first immunization date is considered to be 0 week). The third immunization is double the dose and injected intramuscularly in the neck.

[0020] (3) Preparation of serum When the serum antibody level meets the requirement of strong positive detection by goat pox virus ELISA antibody detection kit, blood is collected from the jugular vein aseptically, centrifuged and serum is separated, inactivated at 56°C for 30 minutes, and used as positive control reserve serum (stored at -20°C) after passing the test. The positive control reserve serum is diluted with sample diluent in multiples to determine its titer. According to the determined titer, the positive control reserve serum is appropriately diluted with sample diluent to serve as the positive control serum of this kit.

[0021] The negative control serum is healthy goat serum.

[0022] The enzyme-labeled secondary antibody is a commercial horseradish peroxidase-labeled rabbit anti-sheep IgG antibody.

[0023] The substrate solution A is a citric acid phosphate buffer solution containing 0.6 mg / ml hydrogen peroxide urea, and the substrate solution B is a 0.2 mg / ml tetramethylbenzidine solution, and the two are mixed in a ratio of 1:1 when used. The stop solution is a 2 mol / L sulfuric acid solution.

[0024] The kit also includes a sample diluent and a 20-fold concentrated washing solution; the sample diluent is a 0.01M phosphate buffer containing 5mg / ml casein and a pH value of 7.4; the concentrated washing solution is a 0.01M phosphate buffer containing 0.8% to 1.2% (ml / ml) Tween-20 and a pH value of 7.4.

[0025] The detection procedure of the kit of the present invention is:

[0026] 1. Balance: Take the test kit out of the refrigerated environment and equilibrate it at room temperature for 30 minutes before use; mix the liquid reagent before use.

[0027] 2. Solution preparation: dilute the concentrated washing solution 20 times with distilled water or deionized water to obtain washing buffer solution;

[0028] 3. Set up: 2 negative control wells and 2 positive control wells, and the rest are sample wells to be tested.

[0029] 4. Pre-dilution of the test specimen: Use sample diluent to dilute the test sample serum, negative control serum, and positive control serum at a ratio of 1:20.

[0030] 5. Sample addition: Add 100 μl of the diluted sample to be tested to each well according to the pre-set value. The time span of the sample addition process should be as short as possible.

[0031] 6. Incubation: Vortex to mix, place in a 37°C incubator, and react for 30 minutes.

[0032] 7. Wash the plate: discard the reaction solution, add 300 μl of diluted washing buffer to each well, soak for 15 seconds, discard the washing solution, wash the plate 3 to 5 times continuously and pat dry.

[0033] 8. Add enzyme: Add 100 μl horseradish peroxidase-labeled rabbit anti-goat IgG antibody to each well.

[0034] 9. Incubation: Place in a 37°C incubator and react for 30 minutes.

[0035] 10. Wash the plate: discard the reaction solution, add 300 μl of diluted washing buffer to each well, soak for 15 seconds, discard the washing solution, wash the plate 3 to 5 times continuously and pat dry.

[0036] 11. Color development: Add 100 μl of substrate working solution to each well (substrate working solution is prepared by mixing equal amounts of substrate solution A and substrate solution B, prepared immediately before use), shake to mix, place in a 37°C incubator, and react for 15 minutes in the dark.

[0037] 12. Add 50 μl of color stop solution to each well and shake to stop the reaction.

[0038] 13. Determine the OD of each well 450nm Value (OD should be read within 15 minutes after adding the stop solution to the reaction plate 450nm value).

[0039] Determination of test results:

[0040] 1. Negative control OD 450nm The average value should be ≤0.2, otherwise it is invalid.

[0041] 2. Each test value of the positive control should be between 1.0 and 2.2, otherwise it will be invalid.

[0042] 3. Calculate the critical value: critical value = 0.18 × OD of positive control well 450nm average value;

[0043] 4. Result determination: serum OD to be tested 450nm ≥ critical value, antibody positive; serum OD to be tested 450nm < cut-off value, antibody negative.

[0044] The kit of the present invention can be used to detect goatpox virus antibodies to determine whether the tested animal has goatpox virus antibodies.

[0045] The application of the method in preparing a kit for detecting whether a goat is infected with goat pox virus also falls within the protection scope of the present invention;

[0046] The positive effect of the present invention is that the present invention uses a bioinformatics method to accurately analyze the A27L antigen epitope of the goat pox virus and screen out a peptide segment suitable for ELISA detection. The advantageous peptide segment has the advantages of high sensitivity and strong specificity.

[0047] At the same time, advanced solid-phase peptide synthesis technology is used to synthesize polypeptide antigens for the preparation of coated enzyme-labeled reaction plates.

[0048] In addition, since the coating antigen used in the kit is a chemically synthesized polypeptide, it does not contain foreign proteins and has high purity, which further improves the efficiency of detecting goat pox virus antibodies.

[0049] In summary, the kit uses the antigen peptide of the main antigen site of the chemically synthesized structural protein A27L to coat the enzyme-linked reaction plate, with a small amount of antigen, high sensitivity and strong specificity, and can effectively detect whether there is goat pox virus antibody in sheep serum. The experimental results show that the kit of the present invention has high sensitivity and strong specificity. It can meet the needs of people at different levels and has broad market prospects and good economic and social benefits. DETAILED DESCRIPTION

[0050] The methods in the following embodiments are conventional methods unless otherwise specified.

[0051] Example 1. Preparation of coated antigen for goatpox virus ELISA antibody detection kit

[0052] This experiment uses bioinformatics methods to accurately analyze the antigen epitope of the Goatpox virus strain AV41 (G56-42) A27L gene sequence (EU024477) published by GenBank, screen out suitable peptide segments, and use a fully automatic peptide synthesizer to synthesize 4 peptides, the sequences of which are shown in sequence 1, sequence 2, sequence 3 and sequence 4 in the sequence table, respectively, to prepare coating antigens with a purity of about 80%. The polypeptide synthesis method can be a conventional method. The present invention uses the following method to synthesize the 4 polypeptides of the present invention as the coating source of the kit of the present invention. The polypeptide sequence is as follows:

[0053] Sequence 1: IFPGDDDETNERNIDHIEKTSGDHGHYEDKLLDL

[0054] Sequence 2: SDEEPNMIKIKNDIKKIINER

[0055] Sequence 3: YSSYISINDDEISNILKDSFISNEEMQI

[0056] Sequence 4: KDFVLRLLVLEKLFQTSVKECNSLKNI

[0057] The coated antigen of the present invention can be prepared using the Applied Biosystem fully automatic peptide synthesizer (model 433A).

[0058] Preparation. The Merrifield solid phase synthesis method is used, using Fmoc (9-fluorenylmethyloxycarbonyl, 9-fluorenylmethyloxycarbonyl) modified amino acids, and Rink Amide MBHA resin as a solid phase carrier. The production process includes five parts: solid phase synthesis of peptide antigens, peptide cleavage and identification, antigen purification, freeze drying and storage. The following are explained separately:

[0059] 1. Solid phase synthesis of coated antigen

[0060] 1. Preparation of synthetic reagents

[0061] The amino acid sequences of the synthetic coating antigens are shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

[0062] Prepare appropriate Fmoc-modified amino acids (purchased from NOVA) according to the coated antigen sequence and the synthesis scale, and add them to the corresponding Cartridge. Weigh 5g of resin according to the required synthesis scale, put it into the reaction chamber, tighten the upper and lower lids, label it, and record the name of the synthesized peptide, batch number, TARE of the reaction chamber and the weight of the weighed resin. Load the reaction chamber into the synthesizer. Prepare appropriate amounts of synthesis reagents including 100% NMP, 3% AIM (acetyl imidazole), 35% PIP (piperidine), 100% MeOH (methanol), etc. and place them in the corresponding reagent bottles.

[0063] 2. Detection of synthesizer status

[0064] Check whether the 433A peptide synthesis instrument is operating normally. After turning on the instrument, run the Run Self Test program to check whether the various indicators of the instrument self-test are normal. In addition, check whether the nitrogen is sufficient and whether the system gauge pressure is normal (the normal gauge pressure of 433A is 10.2psi). Before synthesis, you should have some understanding of the performance of the instrument, so the flow rate of each synthesis reagent should be measured. 433A synthesizer: Send Flow Rate1-18 to the synthesizer, select Main Menu—Module Test—Press Prer or next to find Module A, Module D, Module I, Module I, Module A)—Press Start—Press more to measure or observe. If the flow rate is not appropriate, adjust the valve pressure until it meets the requirements (see Table 1 below for specific test requirements).

[0065] Table 1 Standard table for flow rate detection of peptide synthesizer

[0066] Reagents Bottle No. Module Standard range 35% Piperidine 1 A 1.0~1.2ml 3% AIM 4 D 1.0~1.2ml 100% MeOH 9 I 3.5~4.0ml DIC 8 I 0.45~0.55g 100% NMP 10 A 2.6~2.8ml

[0067] 3. Start of coating antigen synthesis

[0068] In the 433A synthesizer program, send the amino acid sequence to be synthesized as Std Fmoc 1.0Sol DIC90 to the synthesizer. File-New-Sequence-Edit the sequence of the synthesized peptide and save it. File-New-Run, check whether Chemistry is Std Fmoc 1.0Sol DIC 90; whether Sequence is the saved name; set Cycles; save it. Finally, send it to the synthesizer.

[0069] Main Menu—Cycle Monitor—begin, start running.

[0070] 4. Synthesis of coated antigen

[0071] The removal of the Fmoc group, the electron-withdrawing effect of the fluorene ring system of the Fmoc group makes 9-H acidic and easily removed by weaker bases. During the reaction, piperidine (PIP) attacks 9-H, β-elimination forms dibenzofluorene, which is easily attacked by secondary cyclic amines to form stable adducts. After the removal of the Fmoc group, the "-NH2" group is exposed for the synthesis reaction. Then add the next Fmoc group-protected amino acid and 1-hydroxybenzotriazole (HOBT) to the reactor.

[0072] For example, the peptide sequence mentioned above is synthesized from the C-terminus to the N-terminus, and the synthesis steps are repeated in a specific order (the synthesizer automatically completes the steps according to the program, and the specific cycle steps are shown in Table 2). During the process, the reagent dosage and operation status are observed and recorded.

[0073] Table 2 Coating antigen synthesis cycle steps

[0074]

[0075] 5. End of coating antigen synthesis

[0076] After the synthesis of the coated antigen is completed, the synthesizer will automatically stop, and the peptide resin (the peptide is still connected to the resin) will be basically washed clean. Then remove the reactor from the peptide synthesizer, wash the peptide resin with 100% methanol for 3 times, blow dry in a fume hood, and then transfer all the peptide resin to a brown polyethylene bottle, put it in a -20℃ refrigerator, and seal it with a sealing film for later use.

[0077] 2. Lysis and identification of coated antigens

[0078] 1. Cleavage of polypeptide antigens

[0079] The peptide obtained by the above reaction is chemically bonded to the solid phase carrier. It is necessary to separate the peptide from the solid phase carrier by acid hydrolysis with a specific organic strong acid. The acid hydrolysis also removes the protective groups on the functional groups of each amino acid. The steps are as follows:

[0080] Take out the synthesized peptide resin (the peptide is still connected to the resin) from the refrigerator and put it into a 2L round-bottom flask. Add 90ml of trifluoroacetic acid (TFA), 10ml of tripropylsilane (TIS) and a magnetic stirrer to the flask in a fume hood. Then place the flask stably on a magnetic stirrer and continue stirring at room temperature for 1 hour until the reaction is complete. After the reaction is completed, use a rotary evaporator with a cold trap to continuously evaporate for 30 to 120 minutes to remove TFA from the crude product. Then use dimethylformamide (DMF) to wash the crude product of the peptide antigen several times, and finally filter the mixed resin with a sand core funnel to obtain the coated antigen.

[0081] 2. Identification of coated antigen

[0082] After the peptide antigen is synthesized, matrix-assisted laser desorption time of flight mass spectrometry (MODAL-TOF) and reversed-phase high pressure liquid chromatography (RP-HPLC) are used for qualitative and quantitative analysis, and common amino acid analysis is used to identify the synthesized peptide.

[0083] 3. Coated antigen purification

[0084] The cyclized polypeptide antigen is ultrafiltered using a circulating tangential filtration membrane package (using the Tangential Flow Device circulating tangential filtration membrane package produced by PALL and its matching peristaltic pump). As a macromolecule, the polypeptide antigen cannot pass through a filter membrane with a certain pore size, while small molecular impurities formed or introduced during the early synthesis process and the later cyclization reaction can pass through the filter membrane. Then sterilize it through a filter with a pore size of 0.2μm, and the final solution is divided into sterile plastic bottles and labeled. The name, number, production batch number, concentration, production date, shelf life and storage conditions of the polypeptide are indicated on the label. After division, it is stored at -20℃ or -40℃ for use.

[0085] 4. Freeze-drying of coated antigen

[0086] In order to facilitate long-term storage and transportation, the coated antigen needs to be freeze-dried to obtain a solid polypeptide. The pre-frozen coated antigen is placed on a Labconco freeze dryer for drying to obtain a solid coated antigen. After packaging, a label is affixed, indicating the name, number, production batch number, concentration, production date, shelf life and storage conditions of the polypeptide.

[0087] Example 2: Preparation of positive control serum for goat pox virus ELISA antibody detection kit

[0088] (1) Animals used in the production were healthy goats aged 6 months, which were isolated and observed for 7 days.

[0089] (2) The immunogen is a commercial goatpox live vaccine. Three immunizations are performed according to the immunization dose provided in the instructions, at 0, 3 and 6 weeks (the first immunization date is considered to be 0 week). The third immunization is double the dose and injected intramuscularly in the neck.

[0090] (3) Preparation of serum When the serum antibody level meets the requirement of the goat pox virus ELISA antibody detection kit to be strongly positive, blood is collected from the jugular vein aseptically, centrifuged and the serum is separated, inactivated at 56°C for 30 minutes, and used as positive control reserve serum (stored at -20°C) after passing the test. The positive control reserve serum is diluted with sample diluent in multiples to determine its titer. According to the titer determined, the positive control reserve serum is appropriately diluted with sample diluent to make the OD value between 1.8 and 2.2, which is the positive control serum of the kit.

[0091] Example 3. Preparation of Goat Pox Virus ELISA Antibody Detection Kit

[0092] Goatpox virus ELISA antibody test kit includes:

[0093] (1) 96-well detachable polystyrene ELISA plate coated with goatpox virus synthetic peptide antigen; 2×96 wells.

[0094] (2) Positive control serum: The highly immune serum prepared by immunization with commercial goat pox live vaccine is appropriately diluted with sample diluent and used as the positive control serum of this kit (1 tube, 1.5 ml / tube).

[0095] (3) Negative control serum: healthy goat serum, used as the negative control serum of the kit (1 tube, 1.5 ml / tube).

[0096] (4) Enzyme-labeled secondary antibody: Commercial horseradish peroxidase-labeled rabbit anti-sheep IgG (purchased from Sigma, catalog number A5420) was used as the stock solution and diluted 1:30,000 (2 bottles, 12 ml / bottle).

[0097] (5) Sample diluent: 0.01 M phosphate buffer with a pH of 7.4 and containing 5 mg / ml casein (1 bottle, 24 ml / bottle).

[0098] (6) Substrate solution A: citric acid phosphate buffer containing 0.6 mg / ml hydrogen peroxide urea (1 bottle, 12 ml / bottle)

[0099] (7) Substrate solution B: 0.2 mg / ml tetramethylbenzidine solution (1 bottle, 12 ml / bottle).

[0100] (8) Stop solution: 2 mol / L sulfuric acid solution (1 bottle, 12 ml / bottle).

[0101] (9) 20-fold concentrated washing solution: 0.01 M phosphate buffer with a pH of 7.4 and a concentration of 0.8% to 1.2% (ml / ml) Tween-20 (2 bottles, 50 ml / bottle).

[0102] If necessary, the kit may also include a serum dilution plate (2 plates, 96 wells / plate) for diluting serum samples.

[0103] The preparation method of the 96-well detachable polystyrene enzyme-linked reaction plate coated with a synthetic peptide antigen of goat pox virus is as follows: 1. The polypeptide antigen prepared in Example 1 is dissolved in a carbonate solution with a pH of 9.6, and then added to a 96-well polystyrene enzyme-linked reaction plate, 200 ng of polypeptide per well (two polypeptide antigen combinations are coated according to a mass ratio of 1:1, and the total coating amount is 200 ng of polypeptide per well; three polypeptide antigens are coated according to a mass ratio of 1:1:1, and the total coating amount is 200 ng of polypeptide per well; four polypeptide antigens are coated according to a mass ratio of 1:1:1:1, and the total coating amount is 200 ng of polypeptide per well), placed at 2 to 8° C. for 8 to 12 hours to allow the polypeptide antigen to fully combine with the enzyme-linked reaction plate, and then PBS buffer containing 10 mg / ml bovine serum albumin (BSA) pH 7.4 is added at 300 μl / well, blocked at 4° C. overnight, dried, and sealed and stored at 4° C. after the enzyme-linked reaction plate is dried.

[0104] Example 4: Method for using the goat pox virus ELISA antibody detection kit

[0105] 1. Balance: Take the test kit out of the refrigerated environment and equilibrate it at room temperature for 30 minutes; mix the liquid reagent before use.

[0106] 2. Liquid preparation: dilute the concentrated washing solution 20 times with distilled water or deionized water to obtain washing buffer; 3. Set up: 2 negative control wells and 2 positive control wells, and the rest are sample wells to be tested.

[0107] 4. Pre-dilution of the test specimen: Use sample diluent to dilute the test sample serum, negative control serum, and positive control serum at a ratio of 1:20.

[0108] 5. Sample addition: Add 100 μl of the diluted sample to be tested to each well according to the pre-set value. The time span of the sample addition process should be as short as possible.

[0109] 6. Incubation: Vortex to mix, place in a 37°C incubator, and react for 30 minutes.

[0110] 7. Wash the plate: discard the reaction solution, add 300 μl of diluted washing buffer to each well, soak for 15 seconds, discard the washing solution, wash the plate 3 to 5 times continuously and pat dry.

[0111] 8. Add enzyme: Add 100 μl horseradish peroxidase-labeled rabbit anti-goat IgG antibody to each well.

[0112] 9. Incubation: Place in a 37°C incubator and react for 30 minutes.

[0113] 10. Wash the plate: discard the reaction solution, add 300 μl of diluted washing buffer to each well, soak for 15 seconds, discard the washing solution, wash the plate 3 to 5 times continuously and pat dry.

[0114] 11. Color development: Add 100 μl of substrate working solution to each well (substrate working solution is prepared by mixing equal amounts of substrate solution A and substrate solution B, prepared immediately before use), shake to mix, place in a 37°C incubator, and react for 15 minutes in the dark.

[0115] 12. Add 50 μl of color stop solution to each well and shake to stop the reaction.

[0116] 13. Determine the OD of each well 450nm Value (OD should be read within 15 minutes after adding the stop solution to the reaction plate 450nm value).

[0117] Determination of test results:

[0118] 1. Negative control OD 450nm The average value should be ≤ 0.2, otherwise it is invalid.

[0119] 2. Each test value of the positive control should be between 1.0 and 2.2, otherwise it will be invalid.

[0120] 3. Calculate the critical value: critical value = 0.17 × OD of positive control well 450nm average value;

[0121] 4. Result determination: serum OD to be tested 450nm ≥ critical value, antibody positive; serum OD to be tested 450nm < cut-off value, antibody negative.

[0122] Example 5, sensitivity test

[0123] Fifteen batches of goatpox virus ELISA antibody detection kits (batches ZM-GTP01 to ZM-GTP15) prepared according to the method of Example 3 were used to detect 30 goatpox live vaccine immunized goat sera collected from the clinic according to the method of using the goatpox virus ELISA antibody detection kit. The experimental results are shown in Table 3. The sensitivity of the goatpox virus ELISA antibody detection kit of batch ZM-GTP01 of the present invention to the 30 sera to be tested is 26.7% (8 / 30); the sensitivity of the goatpox virus ELISA antibody detection kit of batch ZM-GTP02 of the present invention to the 30 sera to be tested is 26.7% (8 / 30); The sensitivity of the test kit to 30 samples of sera to be tested is 23.3% (7 / 30); the sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP03 of the present invention to 30 samples of sera to be tested is 70.0% (21 / 30); the sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP04 of the present invention to 30 samples of sera to be tested is 40.0% (12 / 30); the sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP05 of the present invention to 30 samples of sera to be tested is 30.0% (9 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP06 of the present invention to 30 samples of sera to be tested is 73.3% (22 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP07 of the present invention to 30 samples of sera to be tested is 50.0% (15 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP08 of the present invention to 30 sera to be tested is 73.3% (22 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP09 of the present invention to 30 sera to be tested is 46.7% (14 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP10 of the present invention to 30 sera to be tested is 93.3% (28 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP11 of the present invention to 30 sera to be tested is 80.0% (24 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP12 of the present invention to 30 sera to be tested is 80.0% (24 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP13 of the present invention to 30 sera to be tested is 90.0% (27 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP14 of the present invention to 30 sera to be tested is 83.3% (25 / 30). The sensitivity of the goatpox virus ELISA antibody detection kit of batch number ZM-GTP15 of the present invention to 30 sera to be tested is 90.0% (27 / 30).Among them, ZM-GTP10 (sequence 3 + sequence 4) has the highest positive detection rate for 30 immune sera. The polypeptide combination of sequence 3 and sequence 4 is preferably used as the coated antigen peptide of the kit.

[0124] Table 3 Sensitivity test results

[0125] Kit batch number Detection rate Sensitivity ZM-GTP01 (Sequence 1) 8 / 30 26.7% ZM-GTP02 (Sequence 2) 7 / 30 23.3% ZM-GTP03 (Sequence 3) 21 / 30 70.0% ZM-GTP04 (Sequence 4) 12 / 30 40.0% ZM-GTP05(sequence 1+sequence 2) 9 / 30 30.0% ZM-GTP06 (sequence 1 + sequence 3) 22 / 30 73.3% ZM-GTP07 (sequence 1 + sequence 4) 15 / 30 50.0% ZM-GTP08 (sequence 2 + sequence 3) 22 / 30 73.3% ZM-GTP09 (sequence 2 + sequence 4) 14 / 30 46.7% ZM-GTP10 (sequence 3 + sequence 4) 28 / 30 93.3% ZM-GTP11(sequence 1+sequence 2+sequence 3) 24 / 30 80.0% ZM-GTP12 (sequence 1 + sequence 2 + sequence 4) 16 / 30 53.3% ZM-GTP13 (sequence 1 + sequence 3 + sequence 4) 27 / 30 90.0% ZM-GTP14 (sequence 2+sequence 3+sequence 4) 25 / 30 83.3% ZM-GTP15 (sequence 1 + sequence 2 + sequence 3 + sequence 4) 27 / 30 90.0%

[0126] Example 6: Specificity test

[0127] 15 batches of goat pox virus ELISA antibody detection kits (batches ZM-GTP01 to ZM-GTP15) prepared according to the method of Example 3 were used to detect 30 healthy goat sera, 2 sheep Brucella positive sera, 2 sheep foot-and-mouth disease virus type O positive sera, and 2 sheep foot-and-mouth disease virus type A positive sera according to the use method of the goat pox virus ELISA antibody detection kit. The specific detection results of the kit are shown in the following table (Table 4). The results of batches ZM-GTP01 to ZM-GTP15 for 30 healthy goat sera, 2 sheep Brucella positive sera, 2 sheep foot-and-mouth disease virus type O positive sera, and 2 sheep foot-and-mouth disease virus type A positive sera were all negative, with a specificity of 100%.

[0128] Table 4 Specificity test results of goat pox virus ELISA antibody test kit

[0129]

[0130]

[0131] Example 7: Comparison with commercially available test kits

[0132] The preferred ZM-GTP10 batch kit in Example 3 was used to test 60 goat sera collected from the clinic according to the method of use of the goat pox virus ELISA antibody detection kit described in Example 4 and the instructions of the commercially available goat pox indirect ELISA antibody detection kit, and the coincidence rates of the two were compared. After testing, the positive detection rate of the kit for 60 clinical sera was 70.0% (42 / 60), and the positive detection rate of the commercially available goat pox indirect ELISA antibody detection kit for 60 clinical sera was 66.7% (40 / 60). There were 38 samples that were all positive in the two kits, and 16 samples that were all negative. The coincidence rate between the two was 90.0% (54 / 60), which was relatively high.

[0133] Table 5 Results of the concordance rate between the goatpox virus ELISA antibody detection kit and the commercially available kits

[0134]

Claims

1. A goatpox virus antigen epitope polypeptide composition, which is composed of the polypeptide shown in sequence 3 in the sequence list and the polypeptide shown in sequence 4 in the sequence list.

2. The goatpox virus antigen epitope polypeptide composition according to claim 1, characterized in that: The mass ratio of the polypeptide shown in Sequence 3 and the polypeptide shown in Sequence 4 is (0.5-1.5):(0.5-1.5); preferably, their mass ratio is 1:

1.

3. A goatpox virus ELISA antibody detection kit, comprising an enzyme-linked reaction plate, a positive control serum, a negative control serum, and an enzyme-labeled secondary antibody, wherein the enzyme-linked reaction plate is coated with the goatpox virus antigen epitope polypeptide composition according to claim 1 or 2.

4. The enzyme-linked immunosorbent assay kit according to claim 3, characterized in that: The enzyme-linked reaction plate is a detachable 96-well ELISA plate; the goat pox virus antigen epitope polypeptide is obtained by chemical artificial synthesis.

5. The ELISA kit according to claim 3, characterized in that: The method for obtaining the enzyme-linked reaction plate is as follows: the goatpox virus antigen epitope polypeptide composition according to claim 1 or 2 is dissolved in 100 μl of a carbonate solution with a pH of 9.6, and then added to a 96-well polystyrene enzyme-linked reaction plate, with 200 ng of the goatpox virus antigen epitope polypeptide composition according to claim 1 added to each well, and placed at 2 to 8° C. for 8 to 12 hours to allow the goatpox virus A27L antigen epitope polypeptide to fully combine with the enzyme-linked reaction plate, and then 300 μl / well of a PBS buffer with a pH of 7.4 containing 0.01 g / ml bovine serum albumin is added, and the plate is blocked overnight at 4° C., and after being dried, the enzyme-linked reaction plate is sealed and stored at 4° C. after drying.

6. The ELISA kit according to claim 3, characterized in that: The positive control serum is a highly immune serum prepared after immunization with a commercial goat pox live vaccine.

7. The ELISA kit according to claim 3, characterized in that: The negative control serum is healthy goat serum; the enzyme-labeled secondary antibody is commercial horseradish peroxidase-labeled rabbit anti-goat IgG antibody.

8. The enzyme-linked immunosorbent assay kit according to claim 3, characterized in that: The substrate solution A is a citric acid phosphate buffer solution containing 0.6 mg / ml hydrogen peroxide urea, and the substrate solution B is a 0.2 mg / ml tetramethylbenzidine solution. When used, the two are mixed in a ratio of 1:1; the stop solution is a 2 mol / L sulfuric acid solution.

9. The enzyme-linked immunosorbent assay kit according to claim 3, characterized in that: The kit also includes a sample diluent and a 20-fold concentrated washing solution; the sample diluent is a phosphate buffer solution containing 5 mg / ml casein, 0.01 mol / L, and a pH value of 7.4; the concentrated washing solution is a phosphate buffer solution containing 0.8% to 1.2% Tween-20, 0.01 mol / L, and a pH value of 7.

4.

10. Use of the goatpox virus antigen epitope polypeptide composition according to any one of claims 1 to 2 in the preparation of an enzyme-linked immunosorbent assay kit for detecting goatpox virus antibodies.